ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1437

Journal of Clinical & Experimental Pathology received 1437 citations as per Google Scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Cosmos IF
  • Ulrich's Periodicals Directory
  • RefSeek
  • Directory of Research Journal Indexing (DRJI)
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
  • world cat
  • journal seek genamics
  • j-gate
  • esji (eurasian scientific journal index)
Share This Page

Lung cancer screenings ��? winning battles in the lung cancer war

15th Global Experts Meeting on Pathology and Laboratory Medicine

Syed M Karim

Sarah Cannon Cancer Institute ��? HCA Midwest Health

Posters & Accepted Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681-C2-049

Abstract
Methods: The Medicare eligibility guidelines for screening were followed: Patients aged 55-77 who currently smoke or have quit within the last 15 years with a tobacco smoking history equal to at least 30 pack years. HCA Midwest facilities are ACR (American College of Radiology) accredited and use approved low dose screening techniques. All sites are participating in the ACR National Radiology Data Registry for lung screening â�?�?which will help benchmark outcomes and process of care measures and develop quality improvement programsâ�? (www.acr.org). For the period of January 2016 â�?�? June 2017, data was obtained by each HCA Midwest facility participating in LDCT Lung Screenings. All screenings were read using the lung reporting and data system (LungRADS) classification method. Utilizing Lungview software, reports were obtained by month and included the LungRADS classification. Results: HCA Midwest facilities had 221 lung screenings January â�?�? December 2016 with 16 lungRAD 4 designations and 4 positive lung cancer diagnoses, a 1.8% diagnosis rate. From January-June of 2017, the same facilities had 126 screenings with 11 lungRAD 4 designations and 4 diagnosed lung cancers, a 3% diagnosis rate. Conclusion: Lung cancer screening programs are a valuable tool in preventive medicine. The data shows that we are seeing benefit and expect as the number of screenings increase, so will the number of early stage cancers diagnosed.
Biography
Top